A continuous production system for single-dose plasma albumin products

A continuous production system for single-dose plasma albumin products, utilizing a five-stage chromatography column series connection and online solution preparation, has solved the safety risks and quality issues associated with the low-temperature ethanol method for preparing human serum albumin. This system achieves efficient and safe albumin preparation, suitable for emergency treatment and rapid mass production.

CN123102002APending Publication Date: 2026-11-17HUALAN BIOLOGICAL ENG CHONGQING
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202611501970.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-24
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

The existing low-temperature ethanol method for preparing human serum albumin has high safety risks, low product quality and yield, difficulty in linear scale-up, poor production flexibility, and lacks new rapid albumin preparation equipment that can achieve continuous operation.

Method used

A continuous production system for single-dose plasma albumin products is adopted, including a chromatography unit. Five chromatography columns (first anion exchange column, second anion exchange column, cation exchange column, third anion exchange column and hydrophobic column) are connected in series and combined with online liquid preparation and adjustment to achieve continuous preparation of materials in a closed flow path and avoid dependence on ethanol precipitation.

Benefits of technology

This technology enables the preparation of albumin with high purity, high yield, and rapid processing, reducing production safety risks, shortening the production cycle, meeting the needs of emergency treatment and rapid mass production, and improving the safety of clinical medication and the safety of the production environment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123102002A_ABST
    Figure CN123102002A_ABST
Patent Text Reader

Abstract

This invention relates to the field of blood product manufacturing technology, specifically to a continuous production system for single-dose plasma albumin products. The continuous production system includes a chromatography unit; the chromatography unit comprises a first anion exchange chromatography column, a second anion exchange chromatography column, a cation exchange chromatography column, a third anion exchange chromatography column, and a hydrophobic chromatography column arranged sequentially along the material movement direction. Methods such as the low-temperature ethanol method and the combination of the low-temperature ethanol method with chromatography cannot meet the requirements for rapid preparation of human serum albumin. There is an urgent need to develop a novel rapid albumin preparation device that does not rely on low-temperature ethanol precipitation and can be continuously produced. This technical solution can solve the technical problems of high safety risks, low product quality and yield, difficulty in linear scale-up, and poor production flexibility in the preparation of human serum albumin using the existing low-temperature ethanol method, and has ideal application and promotion prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of blood product manufacturing technology, specifically to a continuous production system for single-dose plasma albumin products. Background Technology

[0002] Human serum albumin is a core blood-based pharmaceutical preparation obtained by separating and preparing blood plasma from healthy individuals. This substance plays several essential physiological regulatory roles, stabilizing plasma colloid osmotic pressure, facilitating the transport of drug molecules and various small molecules within the body, scavenging free radicals generated during metabolism, reducing the excessive production of oxidative free radicals in polymorphonuclear cells, and also possessing a moderate anticoagulant effect. Due to its unique pharmacological value and physiological functions, human serum albumin is widely used in clinical medicine, playing an irreplaceable and crucial therapeutic role in the clinical treatment of various diseases, including shock symptoms caused by blood loss and trauma, burns, hypoproteinemia, and neonatal hyperbilirubinemia.

[0003] Currently, large-scale industrial production of human serum albumin still primarily relies on the low-temperature ethanol precipitation process, also known as the classic Cohn method and its various optimized and improved schemes. Since its development and application, this technology has long held a mainstream position in the global plasma protein separation field and is also the main process choice for the vast majority of blood product companies in China to carry out mass production of albumin. However, the inherent shortcomings of this traditional preparation method are very prominent, greatly limiting the upgrading of finished product quality and the safety control of the production process. First, the entire process uses ethanol as the core precipitation reagent, and ethanol itself is a flammable and explosive hazardous chemical. This not only brings extremely high safety hazards to the entire production process, but also requires the production line to be equipped with a dedicated explosion-proof workshop and a full set of safety protection devices, directly increasing the overall investment in project construction and daily production. Second, the process relies on repeated operations of multiple rounds of precipitation and reconstitution to separate and purify the target protein from impurity proteins. The complicated cyclic process can easily damage the natural molecular structure of albumin, weaken its biological activity, and directly cause a decrease in raw material utilization and product yield. In addition, the separation mode itself has limited resolution and is difficult to completely remove impurities. The high-concentration ethanol environment will further erode the albumin structure. Multiple factors together reduce the purity and overall quality of the final product. In addition, the low-temperature ethanol process also suffers from poor adaptability to large-scale production. The larger the production capacity, the more difficult it is to control the production parameters, making it difficult to guarantee process stability. Furthermore, it lacks the ability to scale up smoothly and linearly. When the laboratory-scale process is transferred to mass production, problems such as parameter loss of control and significant batch quality differences are very likely to occur, making it difficult to flexibly adjust the production capacity according to production needs.

[0004] Currently, neither the low-temperature ethanol precipitation process nor the combined low-temperature ethanol method and chromatography can meet the industry's demand for rapid mass production of human serum albumin. The industry urgently needs to develop a new, continuous, and efficient albumin preparation system that is independent of ethanol precipitation. Developing innovative new technologies and equipment for plasma albumin preparation, overcoming the limitations of traditional processes, has significant practical implications and broad industrial application prospects for promoting high-quality development of the blood products industry and enhancing clinical drug supply capacity. Summary of the Invention

[0005] The present invention aims to provide a continuous production system for single-dose plasma IgG products to solve the technical problems of high safety risks, low product quality and yield, difficulty in linear scale-up and poor production flexibility in the preparation of human serum albumin by low-temperature ethanol method in the prior art, as well as to solve the technical problem of lacking a new set of equipment for rapid albumin preparation that can realize continuous operation.

[0006] To achieve the above objectives, the present invention adopts the following technical solution: A continuous production system for single-dose plasma albumin products includes a chromatography unit; the chromatography unit includes a first anion exchange chromatography column, a second anion exchange chromatography column, a cation exchange chromatography column, a third anion exchange chromatography column, and a hydrophobic chromatography column arranged sequentially along the material movement direction.

[0007] Furthermore, the packing material in the first anion exchange chromatography column, the second anion exchange chromatography column, and the third anion exchange chromatography column is a strong anion exchange chromatography packing material; the packing material in the cation exchange chromatography column is a strong cation exchange chromatography packing material; Preferably, the ligand of the packing material in the cation exchange chromatography column is sulfopropyl; the ligand of the packing material used in the hydrophobic chromatography column is butyl or phenyl. Preferably, the ligand of the packing material in the first and second anion exchange chromatography columns is trimethylaminoethyl; and the ligand of the packing material used in the third anion exchange chromatography column is trimethylquaternary ammonium.

[0008] For chromatography packing materials, the specific information is as follows: The ligands used in cation exchange chromatography are sulfopropyl groups. For example, Unigel 80sp (Suzhou Nanomicro).

[0009] The packing material used for both the first and second anion exchange chromatography processes has a trimethylaminoethyl ligand. For example, Fractogel EMD TMAE(M) (Merck).

[0010] The packing material used in the third anion exchange chromatography has a trimethyl quaternary ammonium ligand. For example, GPQ-60 (Suzhou Bojin).

[0011] The ligands of the packing material used in hydrophobic chromatography are butyl or phenyl, and the matrix of the packing material is cross-linked agarose gel backbone or polyacrylate, specifically Diamond Butyl, Capto phenyl, or Capto Butyl.

[0012] Furthermore, the column specifications of the first anion exchange chromatography column, the second anion exchange chromatography column, the cation exchange chromatography column, the third anion exchange chromatography column, and the hydrophobic chromatography column are 10-100 mm × 20-30 cm.

[0013] Furthermore, the sample inlet of the first anion exchange chromatography column is connected to a first pipeline and a second pipeline, and the sample outlet of the first anion exchange chromatography column is connected to a third pipeline; the second pipeline is used to transport equilibration solution and diluent to adjust and obtain a first chromatographic solution with a pH of 6.8 to 7.7 and a conductivity of 10.0 to 12.0 mS / cm.

[0014] Using the above technical solution, in the first anion exchange chromatography, the pH of the liquid phase is adjusted to 6.8-7.7 and the conductivity is 10.0-12.0 mS / cm to obtain the first chromatographic solution; the first chromatographic solution is loaded into the anion exchange chromatography column, and the flow-through liquid is collected to obtain the first chromatographic flow-through liquid.

[0015] Furthermore, the sample inlet of the second anion exchange chromatography column is connected to the third tubing, and is also connected to a fifth tubing for conveying the equilibration solution and diluent. The fifth tubing is used to adjust and obtain the second chromatographic solution with a pH of 6.0 to 7.2 and a conductivity of 4.0 to 9.0 mS / cm. The sample outlet of the second anion exchange chromatography column is connected to a sixth tubing.

[0016] Using the above technical solution, in the second anion exchange chromatography, the pH of the first chromatography flow-through solution is adjusted to 6.0-7.2 and the conductivity is 4.0-9.0 mS / cm to obtain the second chromatography solution; the second chromatography solution is loaded into the anion exchange chromatography column, and the flow-through solution is collected to obtain the second chromatography flow-through solution.

[0017] Furthermore, the injection end of the cation exchange chromatography column is connected to the sixth tubing, and is also connected to the eighth tubing for conveying the equilibration solution and diluent. The eighth tubing is used to adjust and obtain the cation exchange chromatography solution with a pH of 5.2 to 5.4 and a conductivity of 0.5 to 2.0 mS / cm. The effluent end of the cation exchange chromatography column is connected to the ninth tubing.

[0018] Using the above technical solution, in cation exchange chromatography, the pH of the second chromatography flow-through solution is adjusted to 5.2-5.4 and the conductivity is 0.5-2.0 mS / cm to obtain the cation chromatography solution to be cationized; the cation chromatography solution to be cationized is loaded into the cation exchange chromatography column, and the flow-through solution is collected to obtain the cation chromatography flow-through solution.

[0019] Furthermore, the sample inlet of the third anion exchange chromatography column is connected to the ninth tubing, and is also connected to the eleventh tubing for conveying the equilibration solution and diluent. The eleventh tubing is used to adjust and obtain the third chromatographic solution with a pH of 6.5 to 7.6 and a conductivity of 1.5 to 2.5 mS / cm. The sample outlet of the third anion exchange chromatography column is connected to the twelfth tubing.

[0020] Using the above technical solution, after the third anion exchange chromatography, the pH of the cation exchange chromatography flow-through solution is adjusted to 6.5–7.6 and the conductivity to 1.5–2.5 mS / cm to obtain the third chromatography solution; the third chromatography solution is loaded into the anion exchange chromatography column, and the flow-through solution is collected to obtain the third chromatography flow-through solution.

[0021] Furthermore, the sample inlet of the hydrophobic chromatography column is connected to the twelfth tubing, and also to the fourteenth tubing for delivering the equilibration solution and diluent. The fourteenth tubing is used to adjust the pH value to obtain the hydrophobic chromatography solution with a conductivity of 12-82 mS / cm. The sample outlet of the hydrophobic chromatography column is connected to the fifteenth tubing.

[0022] Using the above technical solution, in hydrophobic exchange chromatography, the pH of the third chromatography flow-through solution is adjusted to 7.4-7.6 and the conductivity is adjusted to 12-82 mS / cm to obtain the hydrophobic chromatography solution; the hydrophobic chromatography solution is loaded into the hydrophobic chromatography column, and the flow-through solution is collected to obtain the hydrophobic chromatography flow-through solution.

[0023] Furthermore, the continuous production system for single-dose plasma albumin products also includes a computer and a chromatography unit chassis; the chromatography unit is fixedly mounted on the chromatography unit chassis; The process front end of the first anion exchange chromatography column is also connected to a cryoprecipitation separation unit; the cryoprecipitation separation unit includes a plasma separation kit and a refrigeration component for controlling the ambient temperature of the plasma separation kit; the plasma separation kit includes a first container and a second container located below the first container, with a filter membrane disposed between the first container and the second container; a stirring assembly is disposed inside the first container, and a pressure regulating tube is connected to the second container; More preferably, the plasma separation kit also includes an inverted conical third container disposed below the second container, with a pressurized filter membrane disposed between the second and third containers.

[0024] This solution also provides an application of a single-dose continuous production system for plasma albumin products in the preparation of plasma albumin products, wherein the rapid preparation takes 3 to 6 hours.

[0025] Furthermore, the purity of albumin in plasma albumin products is ≥95%.

[0026] The aforementioned continuous production system for single-dose plasma albumin products is applied in the preparation of plasma albumin products, and the specific application process is as follows: The plasma is centrifuged or filtered to obtain the liquid phase. The liquid phase is then fed into a single-dose plasma albumin product continuous production system according to this scheme, and subjected to a first anion exchange chromatography, a second anion exchange chromatography, a cation exchange chromatography, a third anion exchange chromatography, and a hydrophobic chromatography in sequence to obtain the plasma albumin product.

[0027] The application includes the following steps: S1 First Anion Exchange Chromatography: The pH of the material to be chromatographically analyzed is 6.8–7.7, and the conductivity is 10.0–12.0 mS / cm.

[0028] The first anion exchange chromatography (material to be chromatographically analyzed: pH 6.8–7.7, conductivity 10.0–12.0 mS / cm) serves as a crude purification step. At a high conductivity, most albumin flows directly through, while impurities are efficiently removed, thus achieving clarification and preliminary impurity removal.

[0029] S2 Second Anion Exchange Chromatography: The pH of the material to be chromatographically analyzed is 6.0–7.2, and the conductivity is 4.0–9.0 mS / cm.

[0030] The second anion exchange chromatography (material to be chromatographically analyzed: pH 6.0–7.2, conductivity 4.0–9.0 mS / cm) was performed under lower pH and conductivity conditions. At this time, albumin still remained in a flow-through state, further separating impurities and further improving albumin purity.

[0031] S3 cation exchange chromatography: The pH of the material to be chromatographically analyzed is 5.2-5.4, and the conductivity is 0.5-2.0 mS / cm.

[0032] Cation exchange chromatography (material to be chromatographically analyzed: pH 5.2–5.4, conductivity 0.5–2.0 mS / cm) is the key purification step in this invention. Within this extremely narrow pH and conductivity window, impurities such as IgG are strongly adsorbed by the cation exchange medium, while albumin flows smoothly through at this pH. Through extensive experiments, the inventors have discovered that this step has very stringent requirements regarding pH and conductivity. A pH deviation exceeding 5.45 or a conductivity deviation exceeding 2.0 mS / cm will result in a sharp decrease in albumin purity.

[0033] S4 Third Anion Exchange Chromatography: The pH of the material to be chromatographically analyzed is 6.5–7.6, and the conductivity is 1.5–2.5 mS / cm.

[0034] The third anion exchange chromatography (material to be chromatographically analyzed: pH 6.5–7.6, conductivity 1.5–2.5 mS / cm) is a fine purification step, which is run at a lower ionic strength. At this time, albumin flows through while trace impurities are efficiently removed, providing a highly clean feed for subsequent hydrophobic chromatography.

[0035] S5 hydrophobic chromatography: The pH value of the material to be chromatographically analyzed is 7.4-7.6, and the conductivity is 12-82 mS / cm.

[0036] Hydrophobic chromatography (material to be chromatographically analyzed: pH 7.4–7.6, conductivity 12–82 mS / cm) utilizes the difference in surface hydrophobicity between albumin and residual trace hydrophobic impurities. Under high-salt conditions, the hydrophobic impurities bind to the medium, while the albumin flows through and is collected. This step effectively removes hydrophobic impurities and polymers that are difficult to separate by ion exchange chromatography, further ensuring the purity of the final product.

[0037] After ultrafiltration, dialysis and concentration, the hydrophobic chromatography flow-through solution is mixed with sodium octanoate and sodium chloride to obtain an intermediate product with a protein content >100 g / L, a sodium octanoate content of 0.120-0.200 mmol / g protein, a sodium chloride content of 50-150 mmol / L, and a pH value of 6.2-7.6. After pasteurization and filtration, the intermediate products are used to obtain albumin products.

[0038] The technical principle of this technical solution is as follows: This invention relates to a continuous production system for single-dose plasma albumin products. The system replaces the traditional low-temperature ethanol precipitation process with a full-chromatographic flow-through mode. Through the synergistic operation of multiple chromatography columns and online solution preparation, it achieves continuous, closed-loop, and linearly scalable rapid preparation of single-dose plasma albumin products from feed to finished product. The system constructs a continuous flow path along the material flow direction, consisting of a first anion exchange chromatography column, a second anion exchange chromatography column, a cation exchange chromatography column, a third anion exchange chromatography column, and a hydrophobic chromatography column. Each chromatography column is directly connected via pipelines, and each column has an independent equilibration / diluent input pipeline at its sample inlet. This allows for precise online control of the pH and conductivity of the chromatographic solutions at each stage within the equipment, eliminating the need for manual transfer or intermediate storage and ensuring the stability and reproducibility of process parameters during continuous operation.

[0039] In this technical solution, the first anion exchange chromatography column serves as the crude purification unit. Its inlet is connected to both a first and a second pipeline. The first pipeline is used to input the plasma liquid phase after treatment by the cryoprecipitation separation unit (or other equipment), while the second pipeline is used to deliver the equilibration solution and diluent. Through online mixing, the first chromatography solution is adjusted to a pH of 6.8–7.7 and a conductivity of 10.0–12.0 mS / cm. Under these conditions, albumin is essentially not adsorbed by the anion exchange packing material and flows directly through, while most other proteins and impurities are retained by the packing material, thus achieving clarification and preliminary impurity removal at the beginning of the process. The outlet of the first anion exchange chromatography column directly enters the inlet of the second anion exchange chromatography column via a third pipeline. The second anion exchange chromatography column is simultaneously connected to a fifth pipeline. Through the online input of the equilibration solution and diluent, the first chromatography flow-through solution is adjusted to a pH of 6.0–7.2 and a conductivity of 4.0–9.0 mS / cm, becoming the second chromatography solution to be processed. Under these lower pH and conductivity conditions, albumin remains in a flow-through state, while more impurities are captured by the anion exchange packing material, further improving albumin purity. Both stages of the anion exchange chromatography column are preferably constructed using strong anion exchange packing material with a trimethylaminoethyl ligand and column dimensions of 10–100 mm × 20–30 cm, thus ensuring high throughput and impurity loading in the equipment structure.

[0040] The cation exchange chromatography column is the key purification unit of this system. Its inlet is connected to the outlet of the second anion exchange chromatography column via a sixth line, and equilibration and diluents are introduced via an eighth line to adjust the flow-through buffer of the second chromatography column online to the pH 5.2–5.4 and conductivity 0.5–2.0 mS / cm, suitable for cation exchange chromatography. This extremely narrow pH and conductivity window is the core equipment parameter control point of this invention. Under these conditions, albumin is in a flow-through state, while impurities such as IgG are strongly adsorbed by the strong cation exchange packing material. The cation exchange chromatography column preferably uses a strong cation exchange packing material with a sulfopropyl ligand, thereby achieving high selectivity for impurities at the equipment level.

[0041] The cation exchange chromatography flow-through obtained from the cation exchange column is introduced into the injection port of the third anion exchange column via the ninth tubing. The third anion exchange column is also connected to the eleventh tubing for introducing equilibration and diluent solutions to adjust the material to a pH of 6.5–7.6 and a conductivity of 1.5–2.5 mS / cm, forming the third chromatographic solution. This step serves as a fine purification unit, where albumin flows through while trace impurities are efficiently removed. The third anion exchange column preferably uses a strong anion exchange packing material with a trimethyl quaternary ammonium ligand, and its outlet end enters the injection port of the hydrophobic column via the twelfth tubing. The hydrophobic column is simultaneously connected to the fourteenth tubing, where equilibration and diluent solutions are adjusted online to obtain a hydrophobic chromatographic solution with a pH of 7.4–7.6 and a conductivity of 12–82 mS / cm. Residual trace impurities and polymers bind to the hydrophobic packing material, while albumin is collected during flow-through. The hydrophobic chromatography column preferably uses a packing material with butyl or phenyl ligands and a cross-linked agarose gel backbone or polyacrylate matrix. The sample outlet end outputs the hydrophobic chromatography flow-through liquid through the fifteenth pipeline to complete the entire process of continuous chromatography separation.

[0042] This invention constructs a continuous production system suitable for single-person plasma samples through an overall configuration of front-end low-temperature cryoprecipitation separation, five-stage tandem chromatography columns, and online liquid preparation between stages. This system is entirely independent of ethanol precipitation, with each process step primarily relying on flow-through collection. The material moves sequentially within a closed pipeline, thereby achieving high-purity, high-yield, rapid, and continuous preparation of albumin products.

[0043] The beneficial effects of this technical solution are as follows: This system uses a full chromatography flow-through mode as its core, eliminating the use of ethanol as a precipitating agent during production and thus eliminating flammable and explosive hazards at the equipment source. Therefore, the production line does not require a dedicated explosion-proof workshop or a full set of explosion-proof safety protection devices, significantly reducing the overall investment in project construction and daily production, while simultaneously improving the level of safety management in the production environment.

[0044] This system connects a first anion exchange chromatography column, a second anion exchange chromatography column, a cation exchange chromatography column, a third anion exchange chromatography column, and a hydrophobic chromatography column sequentially along the direction of material movement, and provides independent equilibrium / diluent input lines at the injection ends of each stage, enabling continuous five-stage chromatographic separation of the material in a closed flow path. Compared with the intermittent operation of multiple rounds of precipitation and reconstitution in the traditional low-temperature ethanol method, this invention eliminates the repeated precipitation, centrifugation, reconstitution, and intermediate storage steps. The rapid preparation time for a single-dose plasma albumin product is only 3-6 hours, significantly shortening the production cycle and meeting the demand for rapid mass production. This solution is particularly suitable for clinical scenarios requiring rapid acquisition of albumin products, such as emergency treatment and rare blood types, overcoming the shortcomings of the traditional low-temperature ethanol method, which has a long production cycle for large-scale mixing and cannot quickly respond to single-dose needs.

[0045] This system uses a single plasma sample as the processing unit. From cryoprecipitation separation to five-stage chromatographic purification, each plasma sample completes the entire process independently in a closed flow path, without mixing with other plasmas. Compared to the traditional low-temperature ethanol method, which requires mixing large batches of plasma before centralized feeding, this invention cuts off the path of contamination from a single plasma sample to the entire batch of products at the equipment source. Even if a single plasma sample is contaminated with pathogens, it only affects that sample and will not cause the entire batch to be scrapped, greatly reducing the risk of pathogen transmission in blood products and improving the safety of clinical medication. Attached Figure Description

[0046] Figure 1 This is a flowchart of the preparation process of the plasma albumin product in Example 1.

[0047] Figure 2 This is a schematic diagram of the overall equipment for preparing plasma albumin products in Example 1.

[0048] Figure 3 This is a schematic diagram of the chromatography column connection of the equipment used to prepare the plasma albumin product in Example 1.

[0049] Figure 4 This is a schematic diagram of the chromatography column connection of the equipment used to prepare the plasma albumin product in Example 2.

[0050] Figure 5 This is a front view of the plasma separation kit of Example 2.

[0051] Figure 6 This is a front view of the cold precipitation separation unit in Example 2.

[0052] Figure 7 This is a front view of the improved plasma separation kit of Example 2. Detailed Implementation

[0053] The present invention will be further described in detail below with reference to embodiments, but the implementation of the present invention is not limited thereto. Unless otherwise specified, the technical means used in the following embodiments and experimental examples are conventional means well known to those skilled in the art, and the materials and reagents used can all be obtained commercially.

[0054] The present invention will be further described in detail below with reference to embodiments, but the implementation of the present invention is not limited thereto. Unless otherwise specified, the technical means used in the following embodiments and experimental examples are conventional means well known to those skilled in the art, and the materials and reagents used can all be obtained commercially.

[0055] The specific reference numerals in the attached figures are as follows: First anion exchange chromatography column 1, Second anion exchange chromatography column 2, Cation exchange chromatography column 3, Third anion exchange chromatography column 4, Hydrophobic chromatography column 5, Cold precipitation separation unit 6, Pump 7, Valve 8, Computer 9, Chromatography unit chassis 10, Fixed surface 11, Grille 12, First pipeline 13, Second pipeline 14, Third pipeline 15, Fourth pipeline 16, Fifth pipeline 17, Sixth pipeline 18, Seventh pipeline 19, Eighth pipeline 20, Ninth pipeline 21, Tenth pipeline 22, Eleventh pipeline 23, Twelfth pipeline 24, Thirteenth pipeline 25, Fourteenth pipeline 26, Fifteenth pipeline 27, Sixteenth pipeline 28, First container 29, Top cover 30, Stirring assembly 31, Motor 32, Filter membrane 33, Pressure regulating pipe 34, Second container 35, Outlet pipe 36, Cold box 37, Pressurized filter membrane 38, Third container 39.

[0056] Example 1 (I) Preparation process of plasma albumin This technical solution is an improvement based on the applicant's prior patented technologies, namely: "CN116236820A A Continuous Production System for Single-Unit Plasma IgG Products" and "CN116574175A A Single-Unit Plasma IgG Product and its Preparation Method". The original solution pertains to the preparation process and equipment for single-unit plasma IgG from frozen raw plasma. This process and equipment are now modified for application in the preparation process of single-unit plasma albumin. The preparation flow for plasma albumin is as follows (see flowchart). Figure 1 ): (1) Raw plasma processing: After the raw plasma is discharged from the warehouse, the surface of the plasma bag is disinfected with 70% to 75% ethanol solution. The plasma bag is then broken open and thawed at a controlled temperature of 0 to 4°C. After thawing, the plasma is centrifuged at a speed of 10,000 rpm or higher and the supernatant is collected. The plasma used in this step (raw plasma) is the human plasma referred to in the Chinese Pharmacopoeia: Human plasma for blood product production is plasma from healthy individuals collected by apheresis for the production of plasma protein products. It is the supernatant after centrifugation to remove cells from the blood and contains proteins, inorganic salts, and water, but does not contain blood cells.

[0057] (2) First Anion Exchange Chromatography: Adjust the pH of the plasma supernatant after centrifugation to 6.8–7.7 and the conductivity to 10.0–12.0 mS / cm. Filter the supernatant using a 0.22 μm filter cartridge (this step can be omitted in a continuous production system) to obtain the first chromatography solution. The preparation of the first chromatography solution can be done without using a 0.22 μm filter cartridge. Through extensive experimental research, the inventors discovered that adjusting the pH and conductivity to the above ranges in this step prevents protein precipitation. Especially in continuous production systems, filtration with a 0.22 μm filter cartridge can be omitted to accelerate production and avoid disruption to production continuity due to protein precipitation. Perform a first anion exchange chromatography experiment on the first chromatography solution to adsorb IgM and coagulation factors. Collect the flow-through containing albumin (the first chromatography flow-through) for the next chromatography step.

[0058] The anion exchange chromatography packing material used in this step is a strong anion exchange chromatography packing material, such as a strong anion exchange chromatography packing material with trimethylaminoethyl (TMAE) as the functional group.

[0059] (3) Second anion exchange chromatography: Adjust the conductivity of the first chromatography flow-through to 6.0–7.2 mS / cm and the pH to 4.0–9.0. After filtration with a 0.22 μm filter cartridge (adjusting the pH and conductivity to the above range will prevent protein precipitation and can be omitted in continuous production systems), obtain the second chromatography solution. Perform a second anion exchange chromatography on the second chromatography solution to remove trace amounts of impurities and protein. Collect the flow-through containing albumin (second chromatography flow-through) for the next chromatography step.

[0060] The anion exchange chromatography packing material used in this step is a strong anion exchange chromatography packing material, such as a strong anion exchange chromatography packing material with trimethylaminoethyl (TMAE) as the functional group.

[0061] (4) Cation exchange chromatography: Adjust the pH of the second chromatography flow-through to 5.2–5.4 and the conductivity to 0.5–2.0 mS / cm (preferably 2.0 mS / cm). Filter the solution using a 0.22 μm filter cartridge (adjusting the pH and conductivity to the above range will prevent protein precipitation and can be omitted in continuous production systems) to obtain the cation exchange chromatography solution. Load the cation exchange chromatography solution onto a cation exchange chromatography column to adsorb IgG and flow through other non-IgG proteins (including the target protein of this protocol—albumin). Collect the flow-through containing albumin (cation exchange chromatography flow-through) for further purification.

[0062] The cation exchange chromatography packing material used in this step is a strong cation exchange chromatography packing material, such as a strong cation exchange chromatography packing material with sulfopropyl (SP) as the functional group.

[0063] The aforementioned steps (1)-(4) are basically the same as those in the applicant's prior patent, which are general procedures for obtaining plasma IgG and albumin. In step (4), plasma IgG and albumin are separated by a chromatography step, and the subsequent operation steps are specific to albumin.

[0064] (5) Third anion exchange chromatography: Adjust the conductivity of the previous cation exchange chromatography flow-through to 1.5–2.5 mS / cm and the pH to 6.5–7.6, and filter using a 0.22 μm filter cartridge (adjusting the pH and conductivity to the above range will prevent protein precipitation; the filtration step can be omitted in a continuous production system) to obtain the third chromatography solution. Load the third chromatography solution onto anion exchange chromatography column to remove trace amounts of impurities and collect the flow-through to obtain the third chromatography flow-through.

[0065] The anion exchange chromatography packing material used in this step is a strong anion exchange chromatography packing material, such as a strong anion exchange chromatography packing material with quaternary ammonium (Q) functional groups. More specifically, a packing material with trimethylaminepropyl functional groups can be selected.

[0066] (6) Hydrophobic chromatography: Collect the flow-through solution from the third chromatography step, adjust the conductivity to 12–82 mS / cm and the pH to 7.4–7.6, and filter it using a 0.22 μm filter cartridge (adjusting the pH and conductivity to the above range will prevent protein precipitation; the filtration step can be omitted in a continuous production system) to obtain the hydrophobic chromatography solution. Load the hydrophobic chromatography solution onto the hydrophobic chromatography column to remove trace amounts of impurities and collect the flow-through solution to obtain the hydrophobic chromatography flow-through solution.

[0067] The hydrophobic chromatography packing material used in this step is phenyl or butyl hydrophobic chromatography packing material, such as DiamondButyl, Captophenyl, or CaptoButyl.

[0068] (7) Subsequent processing steps: Collect the hydrophobic chromatography flow-through, perform ultrafiltration using a 10 kDa ultrafiltration membrane, dialyze 8 times with physiological saline, dialyze 5 times with injection water, and concentrate to a protein content >100 g / L to prepare a product with sodium caprylate 0.120–0.200 mmol / g protein, sodium chloride content 50–150 mmol / L, and pH value 6.2–7.6.

[0069] The albumin-containing products were pasteurized at 60℃±0.5℃ for 10 hours. After filtration through a 0.45±0.22μm filter cartridge, they were sterilized and packaged.

[0070] Albumin content was determined using a Beckman Coulter specific protein analysis system, total protein content was determined using an Yilanbei fully automated biochemical analyzer, and molecular size distribution was determined using liquid chromatography. Albumin purity was calculated as the ratio of sample albumin content to total protein content; albumin yield was calculated based on the ratio of albumin content to unfiltered albumin content at different experimental steps, yielding albumin yields for different steps.

[0071] This process can be used to analyze at least one plasma sample, and the maximum scale-up is theoretically unlimited depending on the size of the chromatography column.

[0072] (II) Plasma albumin preparation system The system can be divided into two types: a stepwise production system and a continuous production system. The stepwise production system includes five chromatography columns, which are loaded sequentially according to the process flow and conventional operating procedures. The solutions to be chromatographically analyzed (first solution, second solution, cation exchange solution, third solution, and hydrophobic solution) are obtained by filtration using a standard 0.22μm filter cartridge. Using a stepwise production system, production can be completed in 2–6 days.

[0073] If a faster production process is required, a continuous production system (continuous flow production design) can be used. See [link to relevant documentation]. Figure 2 and Figure 3 A continuous production system is designed based on a stepwise production system. During the processing of the first, second, cation-phase, third, and hydrophobic solutions, no protein precipitation occurs (achieved through precise pH and conductivity control via online addition of equilibration / diluent between columns), which is one of the fundamental principles enabling a continuous production system.

[0074] like Figure 2 As shown, the plasma albumin preparation equipment of this technical solution includes a computer 9 and a chromatography unit chassis 10. The chromatography unit chassis 10 includes a chassis shell, one side of which is a fixing surface 11 for fixing chromatography columns and other accessories, and another side of which is a grille 12 for assisting heat dissipation of the internal units. Various units and storage tanks (for storing various buffer solutions and intermediate products) are fixed inside the chassis shell. The above settings are conventional settings for chromatography equipment and are all existing technologies, which will not be described in detail here. The main improvement of this technical solution is that, in order to achieve rapid separation and purification of plasma albumin, the connection method and sequence of the chromatography columns have been set. That is, the main improvement lies in the chromatography unit of the plasma albumin preparation equipment fixed on the fixing surface 11 of the chassis shell of the chromatography unit 10.

[0075] like Figure 3As shown, the chromatography unit includes a first anion exchange chromatography column 1, a second anion exchange chromatography column 2, a cation exchange chromatography column 3, a third anion exchange chromatography column 4, and a hydrophobic chromatography column 5, which are connected in sequence by pipelines. Figure 3 Solid lines represent the main material flow pipelines, solid arrows indicate the flow direction, and dashed lines indicate the waste liquid flow direction. In this technical solution, the chromatography column, pipelines, and storage containers are all disposable equipment to ensure that there are no sources of contamination, viruses, bacteria, etc. in the intermediate process. The material flows continuously in the pipeline without stopping, realizing continuous production. The chromatography column, pipelines, pump 7, valve 8, etc. in this technical solution are all conventional components or equipment used in existing technologies for chromatography analysis or production.

[0076] The sample inlet of the first anion exchange chromatography column 1 is connected to a first tubing 13 and a second tubing 14. Both the first and second tubings are equipped with pumps 7 and valves 8 along the direction of material flow. The first tubing 13 is used to transport the supernatant after plasma centrifugation (the preparation method is detailed in step (1) of section (I) above). The second tubing 14 is used to transport the equilibration solution and diluent, which are used to adjust the pH and conductivity of the liquid, respectively. The equilibration solution and diluent can be buffers such as phosphate buffer or citrate buffer. By adding appropriate equilibration and diluent to the material, the pH and conductivity of the chromatographic solution in each step can be ensured to be within the set range. The amount of each and the solute concentration can be calculated through calculation and routine experiments. The equilibration solution and diluent are transported to the second tubing 14 through their respective branch lines. The supernatant after plasma centrifugation completes pH and conductivity adjustment (by mixing the equilibration and diluent) to form the first chromatographic solution, which then enters the first anion exchange chromatography column 1. The sample outlet of the first anion exchange chromatography column 1 is connected to the second anion exchange chromatography column 2 via a third conduit 15, which is connected to a fourth conduit 16. The first chromatographic solution flows through the first anion exchange chromatography column 1, forming the first chromatographic flow solution, which flows through the third conduit 15 to the second anion exchange chromatography column 2. The fourth conduit 16 is used to discharge waste liquid or collect samples (for detecting intermediate process samples). The third conduit 15 is sequentially equipped with a valve 8, a pump 7, and another valve 8, while the fourth conduit 16 is equipped with a valve 8.

[0077] The sample inlet of the second anion exchange chromatography column 2 is connected to the third pipeline 15 and also to the fifth pipeline 17. A pump 7 and a valve 8 are installed on the fifth pipeline 17 along the direction of material flow. The third pipeline 15 is used to transport the first chromatography flow-through solution, and the fifth pipeline 17 is used to transport the equilibration solution and diluent. The first chromatography flow-through solution undergoes pH and conductivity regulation to form the second chromatography solution, which enters the second anion exchange chromatography column 2. The sample outlet of the second anion exchange chromatography column 2 is connected to the cation exchange chromatography column 3 via the sixth pipeline 18, which is also connected to the seventh pipeline 19. The second chromatography solution flows through the second anion exchange chromatography column 2, forming the second chromatography flow-through solution, which flows through the sixth pipeline 18 to the cation exchange chromatography column 3. The seventh pipeline 19 is used to discharge waste liquid or collect samples (for detecting intermediate process samples). The sixth pipeline 18 is sequentially equipped with valve 8, pump 7, and valve 8, and the seventh pipeline 19 is equipped with valve 8.

[0078] The sample inlet of the cation exchange chromatography column 3 is connected to both the sixth tubing 18 and the eighth tubing 20. A pump 7 and a valve 8 are installed on the eighth tubing 20 along the material flow direction. The sixth tubing 18 is used to deliver the second chromatography flow-through solution, while the eighth tubing 20 is used to deliver the equilibration solution, diluent, and eluent. The second chromatography flow-through solution undergoes pH and conductivity regulation to form the cation exchange chromatography solution, which then enters the cation exchange chromatography column 3. The sample outlet of the cation exchange chromatography column 3 is connected to the third anion exchange chromatography column 4 via the ninth tubing 21. The ninth tubing 21 is also connected to the tenth tubing 22, which is used to discharge waste liquid or collect samples (for intermediate process sample detection). The cation exchange chromatography solution flows through the cation exchange chromatography column 3, forming the cation chromatography flow-through solution, which then flows into the third anion exchange chromatography column 4 through the ninth tubing 21. The ninth tubing 21 is sequentially equipped with valve 8, pump 7, and valve 8, while the tenth tubing 22 is equipped with valve 8.

[0079] The sample inlet of the third anion exchange chromatography column 4 is connected to both the ninth tubing 21 and the eleventh tubing 23. Pumps 7 and valves 8 are installed on the eleventh tubing 23 along the direction of material flow. The ninth tubing 21 is used to deliver the cation exchange chromatography flow-through solution, and the eleventh tubing 23 is used to deliver the equilibration solution and diluent. The cation exchange chromatography flow-through solution undergoes pH and conductivity regulation to form the third chromatographic solution, which enters the third anion exchange chromatography column 4. The sample outlet of the third anion exchange chromatography column 4 is connected to the hydrophobic chromatography column 5 via the twelfth tubing 24, which is also connected to the thirteenth tubing 25. The third chromatographic solution flows through the third anion exchange chromatography column 4, forming the third chromatographic flow-through solution, which flows through the twelfth tubing 24 to the hydrophobic chromatography column 5. The thirteenth tubing 25 is used to discharge waste liquid or collect samples (for intermediate process sample detection). The twelfth pipeline 24 is equipped with valve 8, pump 7 and valve 8 in sequence, and the thirteenth pipeline 25 is equipped with valve 8.

[0080] The sample inlet of the hydrophobic chromatography column 5 is connected to both the twelfth tubing 24 and the fourteenth tubing 26. A pump 7 and a valve 8 are installed on the fourteenth tubing 26 along the direction of material flow. The twelfth tubing 24 is used to deliver the third chromatography flow-through solution, and the fourteenth tubing 26 is used to deliver the equilibration solution and diluent. The third chromatography flow-through solution undergoes pH and conductivity regulation to form the hydrophobic chromatography solution, which then enters the hydrophobic chromatography column 5. The sample outlet of the hydrophobic chromatography column 5 is connected to downstream equipment (which can be a collection device or directly connected to a sterilization device) via the fifteenth tubing 27. The fifteenth tubing 27 is also connected to the sixteenth tubing 28, which is used to discharge waste liquid or collect samples (for testing intermediate process samples). A valve 8 is installed on the sixteenth tubing 28. The hydrophobic chromatography solution flows through the hydrophobic chromatography column 5 and flows into the downstream equipment from the fifteenth tubing 27.

[0081] The flow rate is controlled by the pumping speed of pump 7 and the opening percentage of valve 8 in pipelines 13, 14, 15, 17, 18, 20, 21, 23, 24, and 26. For example, the flow rate ratio can be controlled as 5:1:1:2:1:1:1:2:1:1. Under the process conditions of this technical solution, the above flow rate ratio can ensure that the pH and conductivity of the five chromatography solutions are within the required range (see "(I)" for the required range). The parameters can be preset according to conventional methods of the prior art to ensure the above flow rate, and the concentration and amount of equilibrium liquid and diluent can be determined according to conventional methods in the art, so real-time monitoring is not required. A computer 9 can be used to automatically detect and monitor pH, conductivity and perform UV monitoring. Since the flow rate and other parameters have been preset, this technical solution may not require the installation of pH and conductivity monitoring equipment.

[0082] The equipment in this technical solution can process 1 to 10 plasma samples. The five chromatography columns have the following specifications: 10–100 mm (diameter) × 20–30 cm (length). The product (hydrophobic chromatography flow-through solution) prepared by this solution is in solution form and can be directly processed for subsequent sterilization and dispensing without separate preparation, thus saving operating costs. In addition, the preparation time using this technical solution is very short; a single plasma sample can be purified within 3–6 hours.

[0083] Example 2 This embodiment is basically the same as embodiment 1, except that in the preparation process of plasma albumin preparation, in "(1) Raw material plasma treatment", a cold precipitation separation unit is used to separate the material to be loaded onto the column, which is consistent with the cold precipitation separation unit in the prior patents, namely: "CN116236820A A continuous production system for single-person plasma IgG products" and "CN116574175A A single-person plasma IgG product and its preparation method".

[0084] like Figure 4 As shown, in terms of equipment, this embodiment adds a cold precipitation separation unit 6 at the start of the continuous production system in Embodiment 1. For the specific structure of the cold precipitation separation unit 6, please refer to... Figure 5 and Figure 6 The cryoprecipitation separation unit 6 includes a refrigeration component and a plasma separation kit. In this embodiment, the refrigeration component specifically uses a cold box 37. The plasma separation kit includes a first container 29 and a second container 35. The first container 29 is snapped onto the second container 35 and they are sealed to each other. The bottom of the first container 29 is open, and a filter membrane 33 with a pore size of 0.22 μm is sealed at the opening using conventional methods. A top cover 30 is provided on the top of the first container 29, and a stirring assembly 31 is installed in the top cover 30. The stirring assembly 31 includes a rotating shaft and a stirring paddle. The rotating shaft passes through the top cover 30 and is fixed to the output shaft of a motor 32 by screws. The motor 32 is fixed to the top cover 30 by screws. A pressure regulating pipe 34 is connected to the second container 35, and an outlet pipe 36 is connected to the bottom of the second container 35. The outlet pipe 36 is used to connect to the first pipeline 13. The plasma separation kit can be placed entirely in the cold box 37, or it can be placed as follows: Figure 6 As shown, only the first container 29 is placed in the cold box 37, which is fixed to the frame using conventional methods. When using this device, fresh plasma is first poured into the first container 29 under sterile conditions, the top cover 30 is placed on top, and after cooling to 0-2°C, the motor 32 is started to stir the plasma. Simultaneously, the pressure inside the second container 35 is adjusted to negative pressure through the pressure regulating pipe 34. After the fresh plasma is filtered, the filtrate enters the second container 35. After filtration, the filtrate is transported to subsequent processes through the outlet pipe 36, as detailed in Example 1.

[0085] To ensure that the filtered plasma can smoothly and fully enter subsequent processes, the plasma separation kit can be configured as follows: Figure 7The second container 35 is open at the bottom and sealed with a pressurized filter membrane 38. A third container 39 is snapped into the bottom of the second container 35 and they are sealed together. The third container 39 is inverted conical in shape and its bottom is connected to the outlet pipe 36. When using this device, after filtration, the second container 35 is pressurized through the pressure regulating pipe 34, and all the filtrate is transferred to the third container 39. Because the third container 39 is inverted conical in shape, it can be ensured that all the filtrate enters the outlet pipe 36. For details of the subsequent process, please refer to Example 1.

[0086] Example 3 The following explanation uses a single-dose plasma albumin product as an example, with the raw plasma specifically being plasma from healthy individuals. The effectiveness of this equipment and process is illustrated using healthy human plasma as an example. The standard plasma collection specification is 600g / 580ml per bag per person, meaning each bag of raw plasma constitutes one unit, and each unit contains 600g / 580ml of plasma. The equipment in this scheme (either a stepwise or continuous production system) can process 1 to 10 units of raw plasma. The five-step chromatography operation, including the selected packing materials, chromatography column specifications, processing methods, and parameters of the samples to be chromatographically analyzed, is shown in Table 1. To study the process effect of each step, the following experiments did not use a continuous flow production system but instead employed a five-step chromatography stepwise approach (using a stepwise production system).

[0087] Table 1: Process Parameter Settings

[0088] To study the albumin preparation effect, the operation steps and parameter settings for enriching and purifying albumin from healthy human plasma using the system of this technical solution are as follows (unless otherwise specified, the following methods and parameter settings will be used in subsequent experiments): (1) Take a sample of raw plasma, disinfect the surface with 75% ethanol, break the plasma bag, control the temperature at 3℃ to melt, and centrifuge the plasma at a speed of 10000rpm / min or higher and collect the supernatant.

[0089] (2) First Anion Exchange Chromatography: Adjust the pH of the supernatant of the centrifuged plasma to 7.6 (selectable range 6.8–7.7) and the conductivity to 12.0 mS / cm (selectable range 10.0–12.0 mS / cm). Filter the supernatant using a 0.22 μm filter cartridge to obtain the first chromatography solution. Perform the first anion exchange chromatography on the first chromatography solution to adsorb IgM and coagulation factors. Collect the flow-through containing albumin (first chromatography flow-through) for the next chromatography step. In specific operation, the chromatography column used for the first anion exchange chromatography is 26 mm × 25 cm, and the packing material is Fractogel EMD TMAE(M) (Merck). After packing the chromatography column with the packing material, equilibrate the column using sodium citrate-sodium chloride buffer (pH 7.6; 5~20mM sodium citrate, 0.07~0.12M sodium chloride; preferably 15mM sodium citrate, 0.10M sodium chloride). The initial loading volume of the first chromatographic solution is 10mL of the first chromatographic solution / mL of packing material. The above operation is only one specific implementation method. In actual operation, other column specifications and strong anion exchange packing materials can be selected according to the process yield requirements. The column equilibration method can be determined according to the specific packing material selected, and the loading volume is also determined according to the properties of the packing material and the sample conditions, which will not be elaborated further below.

[0090] (3) Second anion exchange chromatography: Adjust the conductivity of the first chromatography flow-through to 6.0 mS / cm (selectable range 4.0–9.0 mS / cm) and the pH to 6.5 (selectable range 6.0–7.2). After filtration with a 0.22 μm filter cartridge, obtain the second chromatography solution. Perform a second anion exchange chromatography on the second chromatography solution to remove trace amounts of impurities and proteins. Collect the flow-through containing albumin (second chromatography flow-through) for the next chromatography step. The selection of the second anion exchange chromatography column and packing material, as well as the loading volume of the second chromatography solution, are the same as in step (2).

[0091] (4) Cation exchange chromatography: Adjust the pH of the second cation exchange buffer to 5.4 (selectable range 5.2-5.4) and the conductivity to 2.0 mS / cm (selectable range 0.5-2.0 mS / cm). Filter with a 0.22 μm filter cartridge to obtain the cation exchange chromatography solution. Load the cation exchange chromatography solution onto the cation exchange chromatography column and collect the flow-through to obtain the cation exchange chromatography flow-through. In specific operation, the chromatography column used for the first cation exchange chromatography is 26 mm × 25 cm, and the packing material is Unigel 80sp (Suzhou Nanomicro). After packing the chromatography column with the packing material, equilibrate the chromatography column with citrate-phosphate buffer (pH 5.4; 0.025-0.05 M disodium hydrogen phosphate, citrate is used to adjust pH; preferably: 0.015 M disodium hydrogen phosphate). The loading volume of the cation exchange chromatography solution is 25 mL of the third cation exchange chromatography solution / mL packing material.

[0092] (5) Third anion exchange chromatography: Adjust the conductivity of the flow-through buffer from the previous cation exchange chromatography to 1.5 mS / cm (selectable range 1.5–2.5 mS / cm) and the pH to 7.6 (selectable range 6.5–7.6). Filter the buffer using a 0.22 μm filter cartridge to obtain the third chromatography buffer. Load the third chromatography buffer onto the anion exchange chromatography column to remove trace amounts of impurities and collect the flow-through buffer to obtain the third chromatography flow-through buffer. In specific operation, the chromatography column used for the third anion exchange chromatography is 16 mm × 25 cm, and the packing material is trimethyl quaternary ammonium strong anion packing material (GPQ-60, Suzhou Bojin, can be used). After packing the chromatography column with the packing material, equilibrate the chromatography column with tromethamine-hydrochloric acid buffer (pH 7.6, conductivity 1.5 mS / cm; 0.01–0.03 M tromethamine, pH adjusted with hydrochloric acid; preferably 0.02 M tromethamine). The loading amount of the third chromatography solution is 180g of the total protein content in the third chromatography solution per L of packing material.

[0093] (6) Hydrophobic chromatography: Adjust the pH of the third chromatography flow-through after filtration to 7.6 (selectable range 7.4-7.6) and the conductivity to 40 mS / cm (selectable range 12-82 mS / cm) to obtain the hydrophobic chromatography solution. Load the hydrophobic chromatography solution onto the hydrophobic chromatography column and collect the flow-through. In specific operations, the chromatography column used for hydrophobic chromatography is 26 mm × 20 cm, and the packing material is Diamond Butyl (butyl-type weakly hydrophobic interaction chromatography). After packing the chromatography column with the packing material, equilibrate the chromatography column with tromethamine-hydrochloric acid-sodium chloride buffer (pH 7.6, conductivity 40 mS / cm; 0.015~0.03 M tromethamine, adjust pH with hydrochloric acid, adjust conductivity with sodium chloride; preferably 0.02 M tromethamine). The loading amount of the hydrophobic chromatography solution is 550 g of total protein in the hydrophobic chromatography solution / L packing material.

[0094] Subsequent operations were carried out in accordance with Example 1, and subsequent experimental studies were conducted using the above-described operating method.

[0095] Experimental Example 1 This experimental example tested the conditions of the sample to be chromatographically analyzed in five steps. Unless otherwise specified, the operation method is the same as the optimal method in Example 3. Other parameter adjustments are shown in Tables 2-6. After adjusting the pH and conductivity values, the albumin yield (calculated based on the total amount of albumin in the material before sample loading and the flow-through liquid in this step, representing the single-step yield) and purity were analyzed. The experimental results are shown in Tables 2-6.

[0096] Table 2: Experimental conditions and results of the first anion exchange chromatography experiment (values ​​are the average of three independent experiments).

[0097] As shown in Table 2, the experimental data indicates that precise requirements are placed on the conductivity and pH of the first chromatography solvent during the first anion exchange chromatography step to efficiently separate albumin from plasma. A high albumin yield can be obtained by controlling the pH at 6.8–7.7 and the conductivity at 10.0–12.0 mS / cm. This method differs from the method in the prior patent (CN116574175A). The prior patent requires the purification of IgG from plasma, thus necessitating adjustments to the conductivity and pH of the first chromatography solvent to 9.0–15.0 mS / cm and 6.8–7.7, respectively, resulting in a wider range of conductivity and pH values. In contrast, this technical solution is specifically designed for albumin in plasma, allowing for a narrower suitable pH and conductivity range. In particular, in this protocol, adjusting the conductivity from slightly below 10.0 mS / cm to 9.0 mS / cm reduces the yield from >90% to 86%; similarly, adjusting the conductivity from slightly above 13.0 mS / cm to 9.0 mS / cm reduces the yield from 99% to 88%. However, this phenomenon does not occur with IgG. This indicates that the albumin enrichment and purification process in this protocol has specific requirements for the pH and conductivity of the pre-chromatographic material. Preferably, the conductivity needs to be controlled at 12.0 mS / cm and the pH at 7.7.

[0098] Table 3: Experimental conditions and results of the second anion exchange chromatography experiment (values ​​are the average of three independent experiments).

[0099] As shown in Table 3, the pH value of the second chromatography solution needs to be controlled between 6.0 and 7.2 (preferably 6.0), and the conductivity needs to be controlled between 4.0 and 9.0 (preferably 5.0) to ensure a high albumin yield.

[0100] Table 4: Experimental conditions and results of cation exchange chromatography (values ​​are the average of three independent experiments)

[0101] As shown in Table 4, the sample pH and conductivity have a significant impact on the yield and purity of albumin in the cation exchange chromatography step, and there are strict requirements for both.

[0102] Under optimal conditions (Experiments 12–14), when the sample pH is controlled at 5.2–5.4 and the conductivity is maintained at 2.0 mS / cm, the yield of albumin in the flow-through solution can reach 93%–97%, and the purity can be stably maintained above 92.6%, achieving a good balance between yield and purity.

[0103] In stark contrast, when the pH value shifted only slightly (Comparative Experiment 4: pH 5.45; Comparative Experiment 5: pH 5.5), even with the conductivity remaining constant, the albumin purity decreased significantly, dropping to 88.8% and 86.8% respectively, a decrease of 4–6 percentage points. Similarly, when the pH was maintained at its optimal value of 5.4, adjusting the conductivity to 1.5 mS / cm (Comparative Experiment 6) or 2.5 mS / cm (Comparative Experiment 7) also resulted in a sharp drop in albumin purity to 80.5% and 83.6% respectively, with the yield also being severely compromised (the yield in Comparative Experiment 6 was only 86%).

[0104] The above comparative results clearly demonstrate that in this chromatographic system, pH and conductivity are not independent, loose parameters, but rather exhibit an extremely narrow synergistic effect. According to conventional knowledge in the art, chromatographic operations typically have a wide operational flexibility, and the influence of each parameter often shows a linear, gradual trend. However, this discovery shows that under the critical conditions of pH 5.2–5.4 and conductivity 2.0 mS / cm, albumin purity and yield simultaneously reach excellent levels far exceeding those in adjacent ranges. Once deviating from this range (e.g., a pH increase of only 0.05 or a conductivity shift of only 0.5 mS / cm), both indicators experience a precipitous deterioration. This nonlinear mutation of performance leap within the critical window and sharp decline outside the window is something that those skilled in the art could not reasonably anticipate through conventional process optimization or linear extrapolation. The unpredictability of its technical effect fully demonstrates the inventiveness of this invention in the cation exchange chromatography separation of IgG and albumin step (with a focus on purifying and enriching albumin).

[0105] Table 5: Experimental conditions and results of the third anion exchange chromatography experiment (values ​​are the average of three independent experiments).

[0106] Table 6: Experimental conditions and results of hydrophobic chromatography (values ​​are the average of three independent experiments)

[0107] The above descriptions are merely embodiments of the present invention, and common knowledge such as specific technical solutions and / or characteristics are not described in detail here. It should be noted that those skilled in the art can make various modifications and improvements without departing from the technical solutions of the present invention, and these should also be considered within the scope of protection of the present invention. These modifications and improvements will not affect the effectiveness of the implementation of the present invention or the practicality of the patent. The scope of protection claimed in this application should be determined by the content of its claims, and the specific embodiments described in the specification can be used to interpret the content of the claims.

Claims

1. A continuous production system for single-dose plasma albumin products, characterized in that: It includes a chromatography unit; the chromatography unit includes a first anion exchange chromatography column, a second anion exchange chromatography column, a cation exchange chromatography column, a third anion exchange chromatography column and a hydrophobic chromatography column arranged sequentially along the material movement direction.

2. The continuous production system for single-dose plasma albumin products according to claim 1, characterized in that: The packing material in the first, second, and third anion exchange chromatography columns is strong anion exchange packing material; the packing material in the cation exchange chromatography column is strong cation exchange packing material. Preferably, the ligand of the packing material in the cation exchange chromatography column is sulfopropyl; the ligand of the packing material used in the hydrophobic chromatography column is butyl or phenyl. Preferably, the ligand of the packing material in the first and second anion exchange chromatography columns is trimethylaminoethyl; and the ligand of the packing material used in the third anion exchange chromatography column is trimethylquaternary ammonium.

3. The continuous production system for single-dose plasma albumin products according to claim 2, characterized in that: The column dimensions of the first anion exchange chromatography column, the second anion exchange chromatography column, the cation exchange chromatography column, the third anion exchange chromatography column, and the hydrophobic chromatography column are 10–100 mm × 20–30 cm.

4. A continuous production system for single-dose plasma albumin products according to any one of claims 1-3, characterized in that: The first anion exchange chromatography column has a first pipeline and a second pipeline connected to its injection end, and a third pipeline connected to its outlet end. The second pipeline is used to deliver equilibration solution and diluent to adjust and obtain a first chromatographic solution with a pH of 6.8 to 7.7 and a conductivity of 10.0 to 12.0 mS / cm.

5. A continuous production system for single-dose plasma albumin products according to any one of claims 1-3, characterized in that: The sample inlet of the second anion exchange chromatography column is connected to the third tubing, and is also connected to the fifth tubing for delivering the equilibration solution and diluent. The fifth tubing is used to adjust and obtain the second chromatographic solution with a pH of 6.0 to 7.2 and a conductivity of 4.0 to 9.0 mS / cm. The sample outlet of the second anion exchange chromatography column is connected to the sixth tubing.

6. A continuous production system for single-dose plasma albumin products according to any one of claims 1-3, characterized in that: The sample inlet of the cation exchange chromatography column is connected to the sixth tubing, and also to the eighth tubing for delivering the equilibration solution and diluent. The eighth tubing is used to adjust the pH value to obtain the cation exchange chromatography solution with a conductivity of 0.5 to 2.0 mS / cm. The sample outlet of the cation exchange chromatography column is connected to the ninth tubing.

7. A continuous production system for single-dose plasma albumin products according to any one of claims 1-3, characterized in that: The sample inlet of the third anion exchange chromatography column is connected to the ninth tubing, and is also connected to the eleventh tubing for delivering the equilibration solution and diluent. The eleventh tubing is used to adjust the pH value to obtain the third chromatographic solution with a conductivity of 1.5 to 2.5 mS / cm. The sample outlet of the third anion exchange chromatography column is connected to the twelfth tubing.

8. A continuous production system for single-dose plasma albumin products according to any one of claims 1-3, characterized in that: The sample inlet of the hydrophobic chromatography column is connected to the twelfth tubing, and also to the fourteenth tubing for delivering the equilibration solution and diluent. The fourteenth tubing is used to adjust the pH value to obtain the hydrophobic chromatography solution with a conductivity of 12-82 mS / cm. The sample outlet of the hydrophobic chromatography column is connected to the fifteenth tubing.

9. A continuous production system for single-dose plasma albumin products according to any one of claims 1-3, characterized in that: The continuous production system for single-dose plasma albumin products also includes a computer and a chromatography unit chassis; the chromatography unit is fixedly mounted on the chromatography unit chassis; The process front end of the first anion exchange chromatography column is also connected to a cryoprecipitation separation unit; the cryoprecipitation separation unit includes a plasma separation kit and a refrigeration component for controlling the ambient temperature of the plasma separation kit; the plasma separation kit includes a first container and a second container located below the first container, with a filter membrane disposed between the first container and the second container; a stirring assembly is disposed inside the first container, and a pressure regulating tube is connected to the second container; Preferably, the plasma separation kit further includes an inverted conical third container disposed below the second container, with a pressurized filter membrane disposed between the second and third containers.

10. The application of a continuous production system for single-dose plasma albumin products according to any one of claims 1-3 in the preparation of plasma albumin products, characterized in that, The rapid preparation takes 3 to 6 hours; the purity of albumin in the plasma albumin product is ≥95%.

Citation Information

Patent Citations

  • Continuous production system for single-person plasma IgG products

    CN116236820A

  • Single plasma IgG product and preparation method thereof

    CN116574175A